8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales.

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We investigated the determinants of daily PrEP use and coverage of condomless anal sex (CAS) by PrEP among men who have sex with men in Wales, UK. We measured PrEP use by electronic monitors and CAS by secure online surveys. We defined PrEP use based on daily medication cap openings and coverage as CAS episodes preceded by ≥ 3 days of PrEP use and followed by ≥ 2 days of PrEP use. We included 57 participants (5463 observations). An STI diagnosis was associated with lower PrEP use but also lower PrEP coverage. Older adults had higher PrEP use. A belief that other PrEP users took PrEP as prescribed was associated with lower PrEP coverage. An STI diagnosis is an important cue for an intervention, reflecting episodes of high-risk sexual behaviour and low PrEP coverage. Other results provide a basis for the development of an evidence-informed intervention for promoting coverage of PrEP.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          The theory of planned behavior

          Icek Ajzen (1991)
          Organizational Behavior and Human Decision Processes, 50(2), 179-211
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

            Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57). Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

              New England Journal of Medicine, 367(5), 399-410
                Bookmark

                Author and article information

                Journal
                AIDS Behav
                AIDS and behavior
                Springer Science and Business Media LLC
                1573-3254
                1090-7165
                May 2023
                : 27
                : 5
                Affiliations
                [1 ] Centre for Trials Research, College of Biomedical & Life Sciences, School of Medicine, Cardiff University, Cardiff, Wales, UK. gillespied1@cardiff.ac.uk.
                [2 ] Radboud University Medical Center, Institute of Health Sciences, IQ Healthcare, Nijmegen, Netherlands.
                [3 ] Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
                [4 ] Imperial College London, London, England, UK.
                [5 ] Centre for Trials Research, College of Biomedical & Life Sciences, School of Medicine, Cardiff University, Cardiff, Wales, UK.
                [6 ] Division of Population Medicine and PRIME Centre Wales, College of Biomedical & Life Sciences, School of Medicine, Cardiff University, Cardiff, Wales, UK.
                [7 ] Public Health Wales NHS Trust, Cardiff, Wales, UK.
                [8 ] Policy, Research and International Development, Public Health Wales, Cardiff, Wales, UK.
                Article
                10.1007/s10461-022-03890-4
                10.1007/s10461-022-03890-4
                9628468
                36322216
                16c4791f-6477-49ba-9446-80d9c02442f8
                © 2022. The Author(s).
                History

                Adherence,Determinants,HIV prevention,MSM,PrEP
                Adherence, Determinants, HIV prevention, MSM, PrEP

                Comments

                Comment on this article